CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three and six month periods ended June 30, 2008.
"Oncolytics experienced a strong second quarter with the reporting of
durable clinical responses to REOLYSIN(R) combination therapy treatment in
refractory head and neck cancer patients," said Dr. Brad Thompson,
President and CEO of Oncolytics. "We are enrolling increasing numbers of
patients in our clinical program for REOLYSIN(R), and the positive results
from these trials are helping us to plan the later-stage development
program for REOLYSIN(R)."
Second Quarter Highlights
Significant Clinical Advances
- Presented positive interim U.S. Phase II sarcoma trial results at the
American Society of Clinical Oncology (ASCO) annual meeting, showing 8
of 16 evaluable patients experienced stable disease for periods
ranging from two to more than ten, 28-day cycles.
- Presented positive interim results from a U.K. combination REOLYSIN(R)
and paclitaxel/carboplatin trial at the British Society of Gene
Therapy (BSGT) conference in Edinburgh. Three head and neck patients
evaluated at that time had excellent clinical and radiological
responses without appreciable toxicity. The dose escalation portion of
this trial was completed in the second quarter.
- Received approval for U.K. and U.S. Phase II clinical trials
investigating REOLYSIN(R) in combination with paclitaxel and
carboplatin, and started patient enrolment in the U.K. trial.
- The U.S. National Cancer Institute started patient enrolment in a
Phase I/II ovarian, peritoneal and fallopian tube cancer trial using
systemic and intraperitoneal administration of REOLYSIN(R).
- Started patient enrolment in a U.K. combination REOLYSIN(R) and'/>"/>
|SOURCE Oncolytics Biotech Inc.|
Copyright©2008 PR Newswire.
All rights reserved